{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973836",
  "id": "02973836",
  "pages": 14,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1134",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m82z5d5rygf8.pdf",
  "summary": "### **Concise Summary of Material Information (Chimeric Therapeutics - Appendix 4C, 30 June 2025)**  \n\n#### **Clinical Highlights:**  \n- **CHM CDH17 Program:**  \n  - Phase 1/2 trial advanced to **Dose Level 2 (150M cells)**; no dose-limiting toxicities observed in initial cohort.  \n  - **FDA Fast Track Designation** granted for **GEP-NETs** (accelerated regulatory pathway).  \n  - Translational data showed **CAR-T persistence up to 6 months** in 2 patients.  \n- **ADVENT-AML Phase 1B Trial:**  \n  - 2/3 patients achieved **Complete Response (CRi)** in frontline AML; 1 had Stable Disease.  \n\n#### **Financial & Capital Raisings:**  \n- **Capital raised (Q2 2025):**  \n  - **$6.6M Placement** (1.65B shares @ $0.004 + 1.65B options).  \n  - **$2.5M R&D Tax Incentive Facility** (non-dilutive).  \n  - **$1M Entitlement Offer** completed (April 2025).  \n- **Cash balance:** **$5.76M** (vs. $5.06M prior quarter).  \n- **Net operating cash outflow:** **$4.7M** (88% R&D/staff costs).  \n- **Funding runway:** **1.22 quarters** (based on current burn).  \n\n#### **Corporate:**  \n- **Board Appointment:** Professor Miles Prince AM (haematology/cell therapy expert) joined as Non-Executive Director.  \n\n*Omitted: Operational details, director bios, non-material site activations.*",
  "usage": {
    "prompt_tokens": 6407,
    "completion_tokens": 368,
    "total_tokens": 6775,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T01:55:32.380885"
}